Aclaris Therapeutics, Inc. has been making waves in the medical and aesthetic dermatology and immunology industry with its novel drugs. The biopharmaceutical company has earned a consensus rating of Moderate Buy from eight brokerages that are presently covering the stock, according to Bloomberg reports. One investment analyst has rated the stock with a sell rating, while seven have issued a buy rating on the company. This highlights that the industry sees potential in Aclaris Therapeutics innovation.

The average one-year price objective among analysts who have covered the stock in the last year is $32.00 this suggests that investors believe theres scope for growth in this space.

Moreover, several hedge funds have recently bought and sold shares of ACRS, adding to positive investor sentiment towards the biotechnology company. For instance, JPMorgan Chase & Co raised its holdings in Aclaris Therapeutics by 20% in Q1 2021, MetLife Investment Management LLC increased its position by 58.5%, Rhumbline Advisers increased its position by 18.1%, Allianz Asset Management GmbH increased its position by 44.2%, and Vanguard Group Inc increased its position by 0.4%. As a result, approximately 95% of the stock is currently owned by institutional investors and hedge funds.

In conclusion, Aclaris Therapeutics is proving to be a game-changer in medical and aesthetic dermatology and immunology treatments with its innovative products earning approval from industry players. The firm certainly looks poised for growth with an expanding investor base looking to capitalize on this success story. As such, it remains well-positioned to sustain its momentum into breakthrough innovations in drug development at both therapeutic and contract research levels for years to come!

Aclaris Therapeutics: A Leader in Biopharmaceutical Research

Aclaris Therapeutics is a biopharmaceutical company that operates with the objective of identifying, developing, and commercializing novel drugs to address medical and aesthetic dermatology and immunology requirements. The firms primary goal is to deliver cutting-edge treatments that cater to unfulfilled needs in medical fields.

HC Wainwright has conducted extensive studies on Aclaris Therapeutics, reducing its target price from $50.00 to $43.00 while maintaining a buy rating on the stock in a research report on March 7th of this year. Similarly, Stifel Nicolaus initiated coverage on shares of Aclaris Therapeutics, setting a buy rating and a $29.00 target price on the stock in December 2016.

Cantor Fitzgerald reiterated an overweight rating and set a $38.00 target price while The Goldman Sachs Group reduced their target price from $25.00 to $21.00 but retained their buy rating on March 7th.

However, StockNews.com initiated coverage on shares of Aclaris Therapeutics in March 2017 by setting a sell rating on the stock.

Despite mixed reviews from equities research analysts, CEO Douglas J. Manion stands strong in his belief about his companys potential for success as he acquired 6,500 shares of the companys business stock at an average cost of $7.74 per share in early March.

On another note, Director Neal Walker sold 25,000 shares of the companys stock for an average cost of $15.25 per share in January this year, valued at approximately $381K.

Shares of Aclaris Therapeutics opened at $8.25 on Thursday with a market capitalization value of over half-a-billion dollars ($550M), P/E ratio -6.20, and beta 0.60. Aclaris Therapeutics has a 1-year low of $5.77 and 1-year high of $18.96, with a 50-day moving average price of $12.02 and a two-hundred day moving average price of $14.56.

Aclaris Therapeutics released its quarterly earnings data on February 23rd, with the biotechnology company revealing earnings per share of ($0.41) for that quarter, which surpassed the consensus estimate of ($0.44) by $0.03.

Analysts predict that Aclaris Therapeutics will post -1.73 EPS for this year, reflecting positive results from recent studies conducted in the previous quarters.

In conclusion, the market conditions and mixed analyst ratings do not undermine Aclaris Therapeutics massive potential as one of the leading biopharmaceutical innovators in todays medical industry.

More here:

Aclaris Therapeutics Emerges as a Promising Player in Medical and ... - Best Stocks